A cardinal feature of asthma is airway hyperresponsiveness (AHR) to spasmogens, many of which activate G protein-coupled receptors (GPCRs) on airway smooth muscle (ASM) cells. Asthma subtypes associated with allergy are characterized by eosinophilic inflammation in the lung due to the type 2 immune response to allergens and proinflammatory mediators that promote AHR. The degree to which intrinsic abnormalities of ASM contribute to this phenotype remains unknown. The regulators of G protein signaling (RGS) proteins are a large group of intracellular proteins that inhibit GPCR signaling pathways. RGS2-and RGS5-deficient mice develop AHR spontaneously. Although RGS4 is upregulated in ASM from patients with severe asthma, the effects of increased RGS4 expression on AHR in vivo are unknown. Here, we examined the impact of forced RGS4 overexpression in lung on AHR using transgenic (Tg) mice. Tg RGS4 was expressed in bronchial epithelium and ASM in vivo, and protein expression in lung was increased at least 4-fold in Tg mice compared with wild-type (WT) mice. Lung slices from Tg mice contracted less in response to the m3 muscarinic receptor agonist methacholine compared with the WT, although airway resistance in live, unchallenged mice of both strains was similar. Tg mice were partially protected against AHR induced by fungal allergen challenge due to weakened contraction signaling in ASM and reduced type 2 cytokine (IL-5 and IL-13) levels in Tg mice compared with the WT. These results provide support for the hypothesis that increasing RGS4 expression and/or function could be a viable therapeutic strategy for asthma.
Asthma is a chronic relapsing/remitting obstructive lung disease that reduces airflow, manifesting as wheezing, dyspnea, and cough. Although the asthmatic phenotype is somewhat heterogeneous, it is characterized universally by airway hyperresponsiveness (AHR), or increased sensitivity to inhaled bronchoconstrictor compounds such as the acetylcholine (ACh) analogs methacholine (MCh) and carbachol (CCh) (1) . AHR results from inflammation of the airways, bronchial smooth muscle spasm, and increased mucus production, typically in the setting of chronic allergen or pollutant exposure (2) . Although the immune response to allergens and the inflammation that is characteristic of asthma has been studied extensively, the contribution of contractile cells (e.g., airway smooth muscle [ASM] cells) to AHR is less clear (3) . It is unknown whether ASM contraction signaling pathways are inherently perturbed in asthma. G protein-coupled receptor (GPCR) activation induces ASM contraction induced by some (but not all) proinflammatory mediators present in the lung, including ACh, histamine, thrombin, bradykinin, leukotrienes, and serotonin. Excitation-contraction signaling in ASM occurs principally through activation of GPCR-heterotrimeric G protein complexes containing Gaq. Ligand stimulation of the receptor induces a conformational change that results in Gaq activation by causing the exchange of the guanosine diphosphate for GTP to give the GTP-bound form of the G protein. The activated G protein then induces phospholipase C activation and the generation of inositol 1,4,5-trisphosphate (IP3). Ultimately, IP3-evoked Ca 21 flux into the cytosol promotes myosin light chain (MLC) phosphorylation, actin polymerization, and the generation of actin filaments aligned axially to facilitate the interaction with myosin, which culminates in cell shortening (4) . A recent study of the contractile properties of ASM showed that ASM cells isolated from patients with asthma were hyperresponsive to histamine and MCh than ASM cells from healthy controls (5) .
RGS proteins comprise a large family with more than 30 members in mammalian cells. These proteins negatively regulate GPCR functions through a conserved RGS domain that mediates binding to Gai and Gaq (6) . RGS proteins bind the GTPbound activated Ga subunit and accelerate GTP hydrolysis by both Gai and Gaq (GTPase-accelerating, or GAP, activity). This hastens the return of the Ga to the inactive GDP-bound form, thus terminating G protein signaling. Genetic knockout of individual RGS proteins in mice and human cells ex vivo has partially elucidated their physiological roles in the regulation of leukocyte trafficking (7) , vascular smooth muscle tone and blood pressure (8) , and neurological functions (9) . By contrast, the physiological functions of RGS proteins in the lung have not been well studied. We have focused on the role of the R4 subfamily of RGS proteins in asthma. The R4 subfamily (RGS1-5, RGS8, RGS13, RGS18, and RGS21) contains the smallest and simplest members of the RGS family in terms of protein sequence. They are comprised of little more than the RGS box, the domain that mediates the GAP activity that is characteristic of all RGS family members. In previous studies, we detected expression of RGS2-5 in ASM cells and lung (10) . RGS5 expression was increased in cultured ASM cells from asthmatic subjects, and this overexpression was associated with attenuated bronchoconstrictor-induced Ca 21 signaling (11). Chronic isoproterenol exposure reduced RGS5 expression in ASM, and small interfering RNA-mediated knockdown of RGS5 enhanced procontractile signaling, suggesting a mechanism underlying the paradoxical risk of increased bronchoconstriction in some patients who frequently use inhaled b-agonists (10). Subsequently, other investigators reported that a single nucleotide polymorphism in Rgs5 was linked to severe asthma in children who responded poorly to bronchodilators (12) . Corticosteroid and long-acting b-agonist (dexamethasone/salmeterol, referred to as CCS/LABA) treatment was associated with upregulation of RGS2, a selective regulator of Gaq, in human bronchial epithelial cells (BEAS-2B), which attenuated the activation (Ca 21 mobilization) of Gqlinked receptors by several ligands, including MCh and histamine (13) . Ectopic RGS2 overexpression in BEAS-2B recapitulated this phenotype, whereas RNA interference-mediated silencing of RGS2 prevented the effects of CCS/LABA. A separate study revealed that CCS/LABA exerted similar RGS2-dependent effects on Gq-mediated signaling in human ASM cells (14) . Tracheal ring contraction and plethysmography studies revealed that
Rgs2
2/2 mice had increased bronchoconstriction in response to MCh compared with wild-type (WT) controls, providing strong evidence that RGS2 is a physiologically relevant regulator of bronchial tone. Two additional studies indicated that RGS2-deficient mice have increased AHR after allergen challenge, in part due to enhanced airway contraction after allergen challenge, and partly due to effects on airway inflammation and remodeling (15, 16) . Although these published works suggest that contextdependent upregulation of expression of RGS2 protects the airways against bronchospasm, no studies have formally examined the effects of forced overexpression of RGS proteins in the lung on AHR.
In a previous study, we used immunohistochemistry to demonstrate increased quantities of RGS4 in the bronchial smooth muscle of airways from patients with severe asthma compared with airways from patients with mild/moderate asthma and controls (17) . We hypothesized that increased RGS4 expression in ASM may act as a feedback mechanism to mitigate bronchoconstriction and AHR in chronic asthma. To test this hypothesis, we evaluated allergen-induced AHR, inflammation, and ASM contraction signaling in mice with forced RGS4 overexpression. We studied bacterial artificial chromosome (BAC) transgenic (Tg) mice, which express both RGS4 and enhanced green fluorescent protein (eGFP). In the transgene, an internal ribosomal entry site (IRES)-eGFP construct is inserted into the 39 untranslated region (UTR) of RGS4. The transgene is expressed under the endogenous Rgs4 promoter, and overexpression of this Tg Rgs4 has not been reported to have any effect on endogenous Rgs4 expression (18, 19) . We found that RGS4 was overexpressed in the lungs of Tg mice, and that the mice were partially protected from AHR due to both reduced airway contraction and an altered inflammatory milieu after allergen sensitization and respiratory mucosal challenge.
Methods
Additional details regarding the materials and methods used in this work can be found in the data supplement.
RGS4 Tg Mice
RGS4-eGFP Tg mice were generated as described previously and obtained from The Jackson Laboratory as described at jax/org https://www.jax.org/strain/007894 (18, 19) . "A C57BL/6J-derived bacterial artificial chromosome (BAC; RPCI-23-82i24) was modified by inserting an IRES2-eGFP construct (and an frt-flanked neomycin resistance cassette) into the 3' UTR of the Rgs4 locus. The neomycin cassette was subsequently removed by FLP-mediated recombination. BAC DNA (z225 kb) from correctly transformed and targeted bacteria was then injected into C57BL/6J x DBA F1 embryos. Tg offspring (founder line 4 (R4BAC4) were established on this B6: DBA mixed genetic background. These mice were subsequently backcrossed to C57BL/6J inbred mice for more than 12 generations. Under the control of the Rgs4 promoter/enhancer elements, transgene expression reports dynamic developmental, regional, and cellular specific expression in developing and mature cerebral cortex neurons across all cortical domains, as well as developing and mature subcortical regions (telencephalon, diencephalon, and brainstem) (18, 19) ."
Acute Allergen Challenge Model
Mice (6-12 weeks old) were sensitized intraperitoneally with Aspergillus fumigatus (Af) crude extract (20 mg; Hollister-Stier) mixed with Imject Alum (20 mg; Pierce) on days 0 and 14. The mice were challenged intranasally with PBS (naive) or Af extract (25 mg) on days 25, 26, and 27. They were killed 24 hours after the last challenge after studies of lung function, followed by organ harvest. All studies were performed in accordance with institutional guidelines provided by the National Institute of Allergy and Infectious Diseases Animal Use and Care Committee under an approved study (ASP LAD3E).
Airway Resistance Measurements in Live Mice
Mice were anesthetized by intraperitoneal injection of a ketamine and xylazine cocktail (100 mg/kg and 10 mg/kg, respectively), followed by transtracheal intubation with a 20 gauge SURFLO Teflon intravenous catheter (Santa Cruz Animal Health). The mice were mechanically ventilated at 160 breaths/min, during which time PBS and increasing doses of MCh (0, 6.25, 12.5, 25, 50, and 100 mg/ml) were administered by nebulization. Airway resistance was measured directly using the Elan RC FinePointe system (Buxco Research Systems). Mean values (6SEM) are presented in cm H 2 O/ml/s.
Results

Lung RGS4 Expression in Tg Mice
To evaluate the effects of RGS4 overexpression on respiratory function in mice, we established several founder Tg lines containing the Rgs4-egfp BAC. We assessed the egfp copy number using real-time quantitative PCR (qPCR) based on standard curves derived from egfp sequence-containing plasmids of known concentrations. We generated several lines of mice containing on average 10-15 copies of the egfp transgene/1,000 copies of GAPDH for further functional studies ( Figure 1A ). These values were highly correlated with the copy number per cell based on a previously established transgene quantification method (data not shown) (20) . To determine whether an increased egfp copy number correlated with increased Rgs4 expression, we quantified total (endogenous and Tg) Rgs4 abundance in cDNA derived from whole lungs of founder mice by qPCR. We used founder mice for this purpose because the BAC construct includes native elements flanking the Rgs4 coding sequences that do not permit ready differentiation of endogenous transcripts from Tg Rgs4 transcripts. Total Rgs4 mRNA expression was z8-to 10-fold higher in the lungs of Tg mice than in the WT mice ( Figure 1B ). Our previous studies and published work have demonstrated that RGS4 is expressed in both the respiratory epithelium and bronchial smooth muscle of human lungs (17) . To determine the anatomical site of RGS4 protein expression in the lungs of Tg mice, we examined GFP expression in frozen sections of lungs from WT and Tg mice by immunostaining with anti-GFP antibody. We identified ASM using an anti-smooth muscle a actin (SMAA) antibody. Whereas no GFP was detected in lungs from WT mice, we observed high GFP expression in bronchial epithelium and smooth muscle surrounding the airways of Tg mice, as evidenced by colocalization with SMAA ( Figure 1C ). We also detected increased total Rgs4 mRNA expression in cultured tracheal smooth muscle cells ( Figure 1D ) (identified by SMAA expression; Figure E1 in the data supplement) by qPCR. We were not able to detect native or Tg RGS4 protein expression by immunoblotting. However, to enhance steady-state levels in both WT and Tg mice, we exploited the known regulation of RGS4 degradation by the proteasome (21, 22) . Using the proteasome inhibitor MG132, we detected endogenous RGS4 in both WT and Tg ASM, and levels in Tg cells were increased z4-fold compared with the WT ( Figure 1E ).
Increased RGS4 Expression Attenuates Airway Contraction
In patients with allergic asthma, inflammatory mediators associated with the T helper type 2 (Th2) response to allergens promotes AHR through multiple mechanisms, including bronchoconstriction, mucus hypersecretion, and airway remodeling (2) . To determine the effects of increased RGS4 levels on AHR in the setting of allergic inflammation, we sensitized and challenged mice with extracts of Af, which contains fungal allergens linked to severe, uncontrolled forms of asthma in humans (23) . After three respiratory challenges on consecutive days with Af or PBS as a control, we measured lung resistance in live, anesthetized mice by plethysmography after exposure to various amounts of nebulized MCh. Compared with mice challenged with PBS alone, mice treated with Af had increased airway resistance after inhalation of MCh (Figure 2A ). Although the responses of PBS-challenged WT and Tg mice were similar, Af-treated Tg mice overexpressing RGS4 had significantly reduced lung resistance in response to MCh compared with Af-treated WT mice. These results suggested that increased RGS4 abundance in lung protects against allergen-induced AHR. To further examine the contribution of bronchoconstriction to this phenotype, we assessed airway contraction in precision-cut lung slices (PCLSs) in response to CCh by microscopy ( Figure 2B ). PCLSs from Tg mice sensitized with Af but challenged with PBS alone had decreased contractile responses to CCh (maximal effect for agonist [E max ] 75.9 6 4 versus 59.62 6 4.5%; P = 0.01, extra sumof-squares F test; Figure 2C ). Airways from WT mice that had been sensitized and challenged with Af contracted significantly more than those from PBS-challenged mice (maximal contraction z80% versus z60%, respectively) in response to CCh, as expected ( Figure 2D ). CCh-induced bronchoconstriction was significantly reduced in airways from Af-challenged Tg mice compared with those from comparably treated WT mice (E max 86.7 6 4.2 versus 73.3 6 4.6%, P = 0.04). From these results, we conclude that RGS4 overexpression reduces PCLS contraction in response to CCh.
Allergen-Induced Leukocyte Recruitment Is Not Affected by RGS4 Overexpression
Mediators associated with allergic inflammation (e.g., IL-13 and TNF-a) may act on ASM cells directly to augment their contractile and synthetic functions (24) . In addition to bronchi, PCLSs contain several cell types-epithelial cells and mast cells are two examples-that could affect ASM contraction indirectly through inflammatory mediator secretion. To determine whether reduced lung inflammation contributed to the attenuated AHR, we compared parameters of lung inflammation induced by Af sensitization and challenge in WT and Tg mice. We specifically assessed leukocyte infiltration, mucus cell hypertrophy, and proinflammatory cytokines in BAL fluid (BALF). We observed a nearly 20-fold increase in the total number of inflammatory cells in BALF from mice sensitized and challenged with Af compared with mice challenged with PBS alone ( Figure 3A) . As anticipated, a substantial increase in the percentage of eosinophils accounted for the difference ( Figure 3B ). Neither the quantity nor the composition of inflammatory cells in the BALF of Tg mice differed substantially from what was observed in the WT. Histological examination of lung sections from WT and Tg PBS-challenged mice revealed no structural differences ( Figure 3C ). In contrast to the lungs from naive mice, the lungs from allergen-sensitized and -challenged mice had prominent peribronchial and perivascular leukocyte infiltrates and mucus cell hypertrophy, as expected, but there was little difference between the lungs of WT and Tg mice. These findings suggest that RGS4 overexpression does not reduce AHR by inhibiting recruitment of inflammatory cells to the lung in response to allergen challenge.
Alterations in the Lung Inflammatory Microenvironment in RGS4 Tg Mice
To determine whether the proinflammatory microenvironment is altered by the overexpression of RGS4 in lung, we assessed BALF cytokines in PBS-or allergenchallenged mice by multiplexed ELISA. Compared with PBS treatment alone, sensitization and challenge with Af led to significantly increased levels of the Th2-associated cytokines IL-4, IL-5, and IL-13 in the BALF of WT mice, but not Tg mice ( Figures 4A-4C ). The levels of IL-5 and IL-13 were significantly reduced in Tg mice compared with the WT, and IL-4 showed a similar trend that did not reach statistical significance. The Th1 cytokine IL-12 was significantly upregulated in BALF from Tg, but not WT, Af-challenged mice compared with PBS-treated mice, but the levels were similar in WT and Tg mice ( Figure 4D ). We did not detect upregulation of other cytokines tested, including IL-1b, IL-9, IL-10, IL-17, eotaxin, IFN-g, and TNF-a, in the Af-treated WT or Tg mice compared with controls (data not shown). Because RGS4 is prominently expressed in epithelial cells (25) , we investigated whether RGS4 overexpression affects the production of epithelial-derived cytokines that are capable of driving allergic inflammation, such as IL-25 and IL-33. We did not find increased levels of IL-25 in BALF from allergenchallenged mice compared with naive mice ( Figure 5A ), but there was a trend toward /s) after administration of the indicated concentrations of nebulized methacholine (MCh) was determined by plethysmography. Graphs represent the mean 6 SEM from 10-13 mice/group, measured in four independent experiments (**P = 0.001;****P , 0.0001, two-way ANOVA, Tukey multiple comparisons of WT versus Tg Aspergillus fumigatus [Af]). (B) Representative images of airway contraction in precision-cut lung slices in response to the indicated doses of carbachol (CCh). (C) Airway contraction in precision-cut lung slices obtained from naive or Af-sensitized and challenged mice treated with increasing doses of CCh was assessed by measuring the airway diameter by microscopy. Graphs are mean 6 SEM of 9-13 mice/group evaluated in four independent experiments (*P = 0.03; **P = 0.009, two-way ANOVA, Bonferroni multiple comparisons). NT = not treated.
increased IL-33 levels in BALF and statistically significant increases in Il33 mRNA expression in whole lungs of allergen-challenged mice compared with PBS-treated mice of either genotype ( Figures 5B and 5C ). There were no significant differences in IL-33 expression in WT versus Tg mice. We also examined expression of the epithelial-related mucin gene Muc5ac, which promotes airway obstruction through increased mucus production. Muc5ac was upregulated in lungs from Af-challenged mice relative to naive animals, but RGS4 overexpression did not significantly affect Muc5ac expression ( Figure 5D ) (26) . Collectively, these findings suggest that RGS4 overexpression dampens the Th2 cytokine response to Af through as yet unknown mechanisms, but reduces AHR through various mucus-independent pathways, including reduced airway contraction.
Increased RGS4 Expression Inhibits Contraction Signaling in ASM
To determine whether RGS4 overexpression attenuates AHR by inhibiting contractioninducing signaling pathways in bronchial smooth muscle, we examined intracellular Figure 6C ). Thus, increased RGS4 expression diminishes excitationcontraction signaling in ASM to mitigate bronchoconstriction.
Discussion
Here, we investigated the effects of overexpression of the GPCR-related regulatory protein RGS4 on acute allergic inflammation in mice. We used Tg mice with extra copies of Rgs4 coding sequences downstream of its endogenous promoter. We showed that increased levels of RGS4 in the lung reduced allergen-evoked airway contraction in vivo and ex vivo after challenge with allergen. Both intrinsically altered contraction signaling in ASM and changes in the lung inflammatory microenvironment appear to contribute to this phenotype. Multiple lines of evidence indicate that variations in expression of RGS4 and several other R4 RGS proteins in the lung modify AHR in both mice and humans owing to their ability to inhibit Gq-mediated ASM contraction and proliferation. Rgs2 knockout mice have spontaneous AHR due to increased ASM Ca 21 signaling and contraction in response to spasmogens. The airways of these mice also have increased peribronchial smooth muscle mass in the absence of allergen challenge caused by faster growth of ASM cells through Erkand phosphatidylinositol 3-kinase (PI3K)-dependent mechanisms (15, 16) . RGS2 expression is decreased in lungs from patients with asthma compared with controls, and two related single nucleotide polymorphisms in the RGS2 promoter linked to decreased RGS2 expression are more prevalent in patients with asthma versus controls (65 versus 44%) (27) . In previous work, we demonstrated increased RGS4 expression in bronchial smooth muscle bundles in lungs from patients with asthma by immunohistochemistry (17) , and the amount of immunoreactive RGS4 correlated with clinical asthma severity. Concurrently, we showed that RGS4 knockdown in PCLS enhanced airway contraction to histamine and ACh, whereas platelet-derived growth factor (PDGF) reduced PCLS contraction by upregulating RGS4 expression. However, the role of RGS4 in AHR in vivo had not been previously evaluated, and no studies have formally tested the impact of increased expression of any RGS protein in the lung on bronchial smooth muscle tone and AHR in a whole animal model. Here, we extended our previous observations by demonstrating that RGS4 overexpression in vivo decreases airway contraction, due in part to blunted GPCR-mediated Ca 21 signaling and MLC phosphorylation in ASM cells.
Previously published work and the current study suggest that increased RGS4 expression in ASM can mitigate AHR in asthma through RGS4's capacity to inhibit bronchoconstriction. However, its impact on asthmatic diathesis may be multifaceted. A previous study reported that forced RGS4 expression in mouse heart driven by the a-myosin heavy chain promoter was maladaptive: hearts exposed to chronic pressure overload became dilated and hypocontractile, followed by rapid clinical decompensation (28) . Similarly, in severe, uncontrolled asthma, airways may be less contractile due to ASM hyperplasia and stiffness, leading to "fixed" airway obstruction that is unresponsive to bronchodilators (29) . Mitogens such as PDGF stimulate the growth of human ASM in part by activating PI3K-dependent pathways. RGS4 and other R4 family members could affect ASM growth through their known physical interactions with the p85 regulatory subunit of Class IA PI3Ks, which occur independently of GAP activity (17, 30, 31) . In a previous study, we demonstrated that small interfering RNA-mediated knockdown of RGS4 expression in human ASM cells reduced PDGF-evoked proliferation and PI3K activity (17) . Here, we did not detect significant differences in the growth of WT and RGS4 Tg ASM cells in culture, nor did we detect any spontaneous increases in peribronchial smooth muscle mass in Tg mice (data not shown). Because the shortterm allergen sensitization and challenge model used here does not feature prominent increases in ASM mass around airways, further studies of Rgs4 genedeleted strains chronically exposed to allergen may be needed to fully evaluate its role in airway remodeling. Finally, recent work has also shown that PI3Kd induces bronchoconstriction in PCLS through RhoA activation, suggesting that RGS4's interaction with PI3K could affect ASM contraction through its regulation of both G protein and PI3K pathways (32) .
RGS4 overexpression reduced some (but not all) parameters of airway inflammation in allergen-challenged Tg mice through unclear mechanisms. Mice deficient in Gq were previously shown to have impaired eosinophil recruitment to lungs after sensitization and challenge with ovalbumin (33) , whereas mice deficient in RGS2, a negative regulator of Gaq, displayed increased eosinophil accumulation in lungs after repeated intranasal inoculations with house dust mite allergen (15) . These findings suggest ORIGINAL RESEARCH the existence of as yet unidentified Gq signaling pathways in leukocytes that promote inflammation. Such pathways could be targets for regulation by RGS4 because it interacts with Gaq. However, our results differ from the above findings in that we observed intact eosinophil recruitment to lungs after allergen exposure in Tg mice, but reduced type 2 cytokine levels in the airways compared with the WT. Variations in the allergen challenge models used in the respective studies could account for these differences. For instance, recent work has demonstrated that fungal challenge of mice leads to a more severe asthma phenotype than that induced by house dust mite, which is associated with higher levels of IL-33 and greater leukocyte numbers in lung tissue (34) . Finally, because IL-13 directly enhances ASM responses to spasmogens, the reduced levels of IL-13 in the lungs of Tg mice are sufficient to explain the reduced AHR we observed in these mice after allergen challenge (35) .
There are several limitations to our study. Congenital forced overexpression of RGS4 might affect many cell types that contribute to lung development and/or function and thus confound our interpretation of lung function. For example, although we detected reduced CCh-induced contraction of PCLS from naive Tg mice compared with WT mice ex vivo, we were unable to discern similar differences in vivo in live mice using direct measurements of airway resistance. Plethysmography takes into account whole lung mechanics, and RGS4 could play roles in other cells (e.g., skeletal muscle) that affect airway resistance and dynamic compliance. PCLS is more sensitive than plethysmography and simply measures luminal narrowing. Finally, the effects of RGS4 overexpression in mice are mostly evident at higher CCh concentrations, affecting E max . In naive mice, it is possible that the effective CCh concentrations that are necessary to see changes in airway resistance in the whole lung are not attainable in live animals due to systemic side effects (e.g., tachycardia, hypotension, and asphyxiation).
The mechanisms by which RGS4 overexpression reduces allergen-induced type 2 cytokines are unclear. Although the precise cellular source(s) of these mediators in various experimental models of allergic asthma has not been fully elucidated, lung structural cells produce a number of cytokines, including IL-25, IL-33, and thymic stromal lymphopoietin. Secretion of these cytokines triggers production of IL-4, IL-5, and IL-13 by various leukocytes, including Th2 and ILC2 cells (36) . ASM cells, for example, produce IL-33 in response to LPS stimulation in a PI3K-dependent manner, and RGS5 overexpression inhibits LPSinduced Il33 expression in ASM. RGS4 could regulate pattern recognition receptor-induced cytokine expression in ASM. RGS4 is also prominently expressed in epithelial cells, which secrete these mediators. However, in this study we did not detect significantly decreased IL-33 expression in allergen-challenged Tg mice compared with the WT. Our studies provide the first proof-ofconcept evidence that overexpression of an RGS protein in lung provides protection against AHR induced by acute allergen challenge. Currently, no compounds that increase RGS activity and could be exploited for treatment are available. However, several cellular mechanisms that modulate RGS4 steady-state levels, such as the ubiquitin-proteasome pathway, have been described (37) . Application of a proteasome inhibitor (such as bortezomib) to the respiratory mucosa might represent a viable strategy for the treatment of asthma, although such inhibitors are likely to affect the steady-state levels of many proteins that contribute to AHR. At present, mouse strains with tissue-specific deletion of RGS4 in ASM and epithelial cells are being generated to fully delineate its regulation of ASM contraction and proinflammatory pathways, respectively, in the setting of acute and chronic allergen exposure. n 
